Showing 2721-2730 of 5689 results for "".
- Norlase Enters Ophthalmic Market With Launch of LEAF Ultra-Compact Green Laser Photocoagulatorhttps://modernod.com/news/norlase-enters-ophthalmic-market-with-launch-of-leaf-ultra-compact-green-laser-photocoagulator/2476999/Norlase announced the FDA 510(k) clearance and immediate commercial launch of LEAF, the company’s flagship laser product for the treatment of retina and glaucoma disease. LEAF allows ophthalmologists to perform laser therapy in almost any exam room, with minimal set-up time and physical space req
- Intelligent Retinal Imaging Systems (IRIS) Partners with Remidio Innovative Solutions to Provide Early Detection Systems for Diabetic Eye Diseasehttps://modernod.com/news/intelligent-retinal-imaging-systems-iris-partners-with-remidio-innovative-solutions-to-provide-early-detection-systems-for-diabetic-eye-disease/2476989/Intelligent Retinal Imaging Systems (IRIS) announced a partnership with Remidio Innovative Solutions to bring their smartphone based non-mydriatic fundus camera to the U.S. market. Coupling the IRIS software and services program with an affordable and high-quality handheld camera will allow more
- Eyevensys Presents Initial Data from Phase 1/2 Trial of Non-Viral Gene Therapy for Ocular Diseaseshttps://modernod.com/news/eyevensys-presents-initial-data-from-phase-1-2-trial-of-non-viral-gene-therapy-for-ocular-diseases/2476987/Eyevensys this week presented results from part 1 of its phase 1/2 study for noninfectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the nov
- eSight 3 Approved on the US Department of Veterans Affairs (VA) Federal Supply Schedulehttps://modernod.com/news/esight-3-approved-on-the-us-department-of-veterans-affairs-va-federal-supply-schedule/2476985/eSight announced the approval of eSight 3–advanced sight-enhancing glasses for those living with visual impairments–on the United States Department of Veterans Affairs (VA) Federal Supply Schedule (FSS). The registration allows eSight to be included on the FSS through December 2023.<
- Injectsense Demonstrates Animal-to-Cloud IOP Sensing Pathway for Glaucomahttps://modernod.com/news/injectsense-demonstrates-animal-to-cloud-iop-sensing-pathway-for-glaucoma/2476964/Injectsense announced completion of a successful in-vivo animal study of the first implantable sensor and monitoring system designed to collect long-term IOP data. The Injectsense IOP-Connect system creates an organ-to-cloud data connection that enables the clinician to assess glaucoma therapy ef
- Zeiss and Senorics Establish Partnership Focus on Joint Development of Sensor Technologyhttps://modernod.com/news/zeiss-and-senorics-establish-partnership-focus-on-joint-development-of-sensor-technology/2476952/Zeiss announced that it has invested in Dresden, Germany-based Senorics. The partnership aims to further the joint development of small and cost-effective sensors for industrial use in quality assurance and in process monitoring, e.g. on production lines for foodstuffs, agricultural products, pla
- Johns Hopkins Researchers Advance Search For Safer, Easier Way to Deliver Vision-Saving Gene Therapy to The Retinahttps://modernod.com/news/johns-hopkins-researchers-advance-search-for-safer-easier-way-to-deliver-vision-saving-gene-therapy-to-the-retina/2476942/In experiments with rats, pigs, and monkeys, Johns Hopkins Medicine researchers have developed a way to deliver sight-saving gene therapy to the retina. If proved safe and effective in humans, the technique could provide a new, more permanent therapeutic option for patients
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the
- Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligencehttps://modernod.com/news/novartis-and-microsoft-announce-collaboration-to-transform-medicine-with-artificial-intelligence/2476932/Novartis announced a step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort, according to a company news release. The new lab aims to bolster Novartis AI capabilities from research through com
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will